Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this month.

MilliporeSigma Expands Portfolio of Certified Reference Materials for Applied Diagnostics and Testing

Two new products support the identification of the industry-standard alcohol biomarker with high sensitivity. Seven new products ensure accurate identification of omega-3 and omega-6 fatty acids for diagnostic testing.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

MilliporeSigma today announced the expansion of its portfolio of Cerilliant® certified reference materials (CRMs) with nine new Certified Spiking Solutions® used in laboratories around the world. The pre-made stock solutions can be spiked into matrices to create accurate controls and calibrators for applied diagnostics and testing, ensuring reliability in the identification and quantification of drugs and endogenous biomarkers.

“Our portfolio of certified reference materials leverages the latest research and techniques from around the world to meet the ever-changing needs of the health care industry,” said Theresa S. Creasey, Head of Strategy, Marketing and Innovation at MilliporeSigma. “MilliporeSigma’s commitment to highly accurate and reliable starting materials helps our customers stay ahead of the curve, ultimately supporting the best possible care and outcomes for patients.”

The new additions to the Cerilliant® product line include two Certified Spiking Solutions® of phosphatidylethanol (PEth), an alcohol biomarker with high sensitivity appropriate for determining moderate to heavy alcohol consumption.(1) Due to its superior sensitivity and specificity, PEth is now widely used to detect recent drinking. To date, a false positive blood PEth test result has yet to be reported.(2)

Seven new Certified Spiking Solutions® of five Omega-3 fatty acids and two Omega-6 fatty acids have also been added to the product line. These fatty acids, the most commonly monitored in clinical and diagnostic testing applications, play a critical role in conditions including coronary heart disease, diabetes mellitus and cancer. Fatty acid levels are evaluated using mass spectrometry to determine patients’ risk of coronary events, to diagnose essential fatty acid deficiency or to monitor patient response with therapies or dietary supplements.(3,4)

Cerilliant® certified reference solutions are manufactured and authorized to ensure the highest level of accuracy. Solutions are used in quantitative mass spectrometry-based applications that range from therapeutic drug monitoring to diagnostic testing and from endocrinology to pharmaceutical research, clinical toxicology and forensic analysis. MilliporeSigma manufactures a comprehensive list of parent drug, metabolite and internal standard Certified Spiking Solutions® used for clinical diagnostic test applications of immunosuppressants, bile acids, vitamins, steroids and hormones, catecholamines, cardiac drugs, antidepressants and pain management drugs.

References
(1) http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/82426
(2) http://www.sciencedirect.com/science/book/9780128003398
(3) http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/82426
(4) http://www.questdiagnostics.com/testcenter/testguide.action?dc=TS_Omega_3_6

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report